MBX Biosciences (MBX) Accumulated Depreciation (2023 - 2026)

MBX Biosciences has reported Accumulated Depreciation for 4 years, with the latest figure at $734000.0 in Q1 2026.

• Quarterly Accumulated Depreciation rose 47.09% year-over-year to $734000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $734000.0 (up 47.09% YoY) and the FY2025 annual result came in at $670000.0, up 58.77% from the prior year.
• Accumulated Depreciation advanced to $734000.0 in Q1 2026 per MBX's latest filing, from $670000.0 in the prior quarter.
• Over five years, Accumulated Depreciation peaked at $734000.0 in Q1 2026 and troughed at $178000.0 in Q4 2023.
• A 4-year average of $504625.0 and a median of $529500.0 in 2025 frame the typical range for Accumulated Depreciation.
• The sharpest annual moves came in 2024 and 2026: Accumulated Depreciation jumped 137.08% in 2024, then jumped 47.09% in 2026.
• Over 4 years, Accumulated Depreciation stood at $178000.0 in 2023, then surged by 137.08% to $422000.0 in 2024, then surged by 58.77% to $670000.0 in 2025, then climbed by 9.55% to $734000.0 in 2026.
• According to Business Quant data, Accumulated Depreciation over the past three periods registered $734000.0, $670000.0, and $610000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.